SynthesisPloS one2017
Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of cancer vaccine therapy in malignant melanoma: a systematic review.International journal of clinical oncology · 2025Pooled it
- Pooled it
- Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2019Pooled it
- Analysis of Characteristics and Risk Factors of Patients with Single Gastric Cancer and Synchronous Multiple Gastric Cancer among 14,603 Patients.Gut and liver · 2024Article
- Novel Mutations Conferring Amoxicillin Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Diagnostic and Therapeutic Management ofHealthcare (Basel, Switzerland) · 2023Review
- Epidemiology of Gastric Cancer: Global Trends, Risk Factors and Premalignant Conditions.Journal of community hospital internal medicine perspectives · 2023Review
- Advances in the Aetiology & Endoscopic Detection and Management of Early Gastric Cancer.Cancers · 2021Review
- Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.Digestive diseases and sciences · 2021Article
- Characteristics and Early Diagnosis of Gastric Cancer Discovered afterGut and liver · 2021Review
- Sharing With Patients the Uncertainties Regarding the Management of Dyspepsia.Frontiers in medicine · 2021Review
- Review
- The Potential Benefits of Vonoprazan asPharmaceuticals (Basel, Switzerland) · 2020Review
- Reversal of the Methylation-Associated Regulation of miR-200a/b byGut and liver · 2020Article
- Pathways of Gastric Carcinogenesis,International journal of molecular sciences · 2020Review
- AGA Technical Review on Gastrointestinal Evaluation of Iron Deficiency Anemia.Gastroenterology · 2020Review
- Article
- Review
- Risk of stomach cancer incidence in a cohort of Mayak PA workers occupationally exposed to ionizing radiation.PloS one · 2020Article
- Can Aminoglycosides Be Used as a New Treatment forInfection & chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHelicobacter pylori infection is strongly associated with gastric cancer occurrence. However, it is unclear whether eradication therapy reduces the risk of gastric cancer occurrence. We evaluated whether H. pylori eradication reduces the risk of primary gastric cancer by using both risk ratio (RR) and risk difference (RD).
methodsSearches of PubMed, EMBASE, Google scholar, the Cochrane Library, and the Japan Medical Abstracts Society as well as those registered in databases of the Cochrane Central Register of Controlled Trials, metaRegister of Controlled Trials, ClinicalTrials.gov, controlled-trials.com, UMIN-CTR, JMACCT-CTR, and JAPIC-CTI between January 1965 and March 2017, supplemented with manual screening. Randomized controlled trials (RCTs) in which eradication therapy were implemented for the interventional group but not for the control group, and assessed the subsequent occurrence of primary gastric cancer as the main outcome. Two authors independently reviewed articles and extracted data. Integrated results for all data were presented as RR and RD.
resultsSeven studies met inclusion criteria. The reductions in risk of primary gastric cancer occurrence in terms of overall RR and RD were 0.67 (95% CI: 0.48 to 0.95) and -0.00 ([95% CI: -0.01 to 0.00]; number needed to treat: 125.5 [95% CI: 70.0 to 800.9]), respectively.
conclusionsThe effectiveness of H. pylori eradication therapy in suppressing the occurrence of primary gastric cancer was significant and comparable to that of previous studies in terms of the estimated RR. However, the estimated RD was slight and not statistically significant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.